Result of General Meeting & Update on Acquisition

RNS Number : 8156B

Venn Life Sciences Holdings PLC

09 October 2015

 

Venn Life Sciences Holdings plc

("Venn" or the "Company"

                                                 Result of General Meeting and Update on Acquisition                                                

The Board of Venn Life Sciences Holdings plc (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that at its General Meeting held earlier today, 9 October 2015, all resolutions were duly passed.

The Placing Shares are expected to be admitted to trading on AIM on Monday 12 October 2015.  The acquisition of Kinesis Pharma BV is scheduled to complete on Friday 16 October 2015 and the Consideration Shares are expected to be admitted to trading on Monday 19 October 2015.

For further information:

Venn Life Sciences Holdings Plc	www.vennlifesciences.com
Tony Richardson, Chief Executive Officer	Tel: [phone]
Jonathan Hartshorn, Chief Financial Officer
Orla McGuinness, Marketing Manager	Tel: [phone]
Zeus Capital (Nominated Adviser and Co-Broker)
Andrew Jones/Phil Walker	Tel: [phone]
Dominic Wilson/Alex Davies	Tel: [phone]
Hybridan LLP (Co-Broker)
Claire Louise Noyce	Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Venn Life Sciences:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 

END

 

 

MSCFMMGGGLNGKZM